Vieira RT, Caixeta L, Machado S, Silva AC, Nardi AE, Arias-Carrion O, et al. Epidemiology of early-onset dementia: a review of the literature. Clin Pract Epidemiol Ment Health. 2013;9:88–95.
Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386:1672–82.
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–77.
Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–14.
Younes K, Miller BL. Frontotemporal dementia: neuropathology, genetics, neuroimaging, and treatments. Psychiatr Clin North Am. 2020;43:331–44.
Spinelli EG, Mandelli ML, Miller ZA, Santos-Santos MA, Wilson SM, Agosta F, et al. Typical and atypical pathology in primary progressive aphasia variants. Ann Neurol. 2017;81:430–43.
Landin-Romero R, Tan R, Hodges JR, Kumfor F. An update on semantic dementia: genetics, imaging, and pathology. Alzheimers Res Ther. 2016;8:52.
Rohrer JD, Guerreiro R, Vandrovcova J, Uphill J, Reiman D, Beck J, et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology. 2009;73:1451–6.
Goldman JS, Farmer JM, Wood EM, Johnson JK, Boxer A, Neuhaus J, et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology. 2005;65:1817–9.
Le Ber I. Genetics of frontotemporal lobar degeneration: an up-date and diagnosis algorithm. Rev Neurol (Paris). 2013;169:811–9.
Reed LA, Wszolek ZK, Hutton M. Phenotypic correlations in FTDP-17. Neurobiol Aging. 2001;22:89–107.
Rowe JB. Parkinsonism in frontotemporal dementias. Int Rev Neurobiol. 2019;149:249–75.
Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature. 1998;391:393–7.
Dumanchin C, Camuzat A, Campion D, Verpillat P, Hannequin D, Dubois B, et al. Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. Hum Mol Genet. 1998;7:1825–9.
Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702–5.
Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. J Neurol. 2019;266:2075–86.
Shi Z, Liu S, Xiang L, Wang Y, Liu M, Liu S, et al. Frontotemporal dementia-related gene mutations in clinical dementia patients from a Chinese population. J Hum Genet. 2016;61:1003–8.
Mao C, Dong L, Li J, Huang X, Lei D, Wang J, et al. Phenotype heterogeneity and genotype correlation of MAPT mutations in a Chinese PUMCH cohort. J Mol Neurosci. 2021;71:1015–22.
He S, Chen S, Xia MR, Sun ZK, Huang Y, Zhang JW. The role of MAPT gene in Chinese dementia patients: a P301L pedigree study and brief literature review. Neuropsychiatr Dis Treat. 2018;14:1627–33.
Borrego-Ecija S, Morgado J, Palencia-Madrid L, Grau-Rivera O, Rene R, Hernandez I, et al. Frontotemporal dementia caused by the P301L mutation in the MAPT gene: clinicopathological features of 13 cases from the same geographical origin in Barcelona, Spain. Dement Geriatr Cogn Disord. 2017;44:213–21.
Ishizuka T, Nakamura M, Ichiba M, Sano A. Familial semantic dementia with P301L mutation in the tau gene. Dement Geriatr Cogn Disord. 2011;31:334–40.
DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245–56.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
Rossini ED, Karl MA. The trail making test a and B: a technical note on structural nonequivalence. Percept Mot Skills. 1994;78:625–6.
Golden CJ. The Stroop color and word test: a manual for clinical and experimental uses. Chicago: Stoelting Co.; 1978.
Wu Q, Hu X, Wen X, Li F, Fu W. Clinical study of acupuncture treatment on motor aphasia after stroke. Technol Health Care. 2016;24 Suppl 2:S691–6.
Wang Y, Cai L, Zhou K, Cui M, Yao S. Biodistribution and dosimetry evaluation for a novel tau tracer [(18)F]-S16 in healthy volunteers and its application in assessment of tau pathology in Alzheimer’s disease. Front Bioeng Biotechnol. 2021;9:812818.
Zhou K, Yang F, Li Y, Chen Y, Zhang X, Zhang J, et al. Synthesis and evaluation of fluorine-18 labeled 2-phenylquinoxaline derivatives as potential tau imaging agents. Mol Pharm. 2021;18:1176–95.
Zhang N, Zhang L, Li Y, Gordon ML, Cai L, Wang Y, et al. Urine AD7c-NTP predicts amyloid deposition and symptom of agitation in patients with Alzheimer’s disease and mild cognitive impairment. J Alzheimers Dis. 2017;60:87–95.
Chen J, Yang X, Zhang Y, Zheng P, Wei C, Mao Z, et al. Reference values for plasma neurofilament light chain (NfL) in healthy Chinese. Clin Chem Lab Med. 2021;59:e153–e6.
Zhang N, Gordon ML, Ma Y, Chi B, Gomar JJ, Peng S, et al. The age-related perfusion pattern measured with arterial spin labeling MRI in healthy subjects. Front Aging Neurosci. 2018;10:214.
Tacik P, Sanchez-Contreras M, DeTure M, Murray ME, Rademakers R, Ross OA, et al. Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) due to microtubule-associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy. Neuropathol Appl Neurobiol. 2017;43:200–14.
Hodges JR, Mitchell J, Dawson K, Spillantini MG, Xuereb JH, McMonagle P, et al. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain. 2010;133:300–6.
Ramos EM, Dokuru DR, Van Berlo V, Wojta K, Wang Q, Huang AY, et al. Genetic screen in a large series of patients with primary progressive aphasia. Alzheimers Dement. 2019;15:553–60.
Gonzalez-Sanchez M, Puertas-Martin V, Esteban-Perez J, Garcia-Redondo A, Borrego-Hernandez D, Mendez-Guerrero A, et al. TARDBP mutation associated with semantic variant primary progressive aphasia, case report and review of the literature. Neurocase. 2018;24:301–5.
Cerami C, Marcone A, Galimberti D, Villa C, Fenoglio C, Scarpini E, et al. Novel missense progranulin gene mutation associated with the semantic variant of primary progressive aphasia. J Alzheimers Dis. 2013;36:415–20.
Le Ber I, Camuzat A, Guillot-Noel L, Hannequin D, Lacomblez L, Golfier V, et al. C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testing. J Alzheimers Dis. 2013;34:485–99.
Rohrer JD, Lashley T, Schott JM, Warren JE, Mead S, Isaacs AM, et al. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain. 2011;134:2565–81.
Han LH, Xue YY, Zheng YC, Li XY, Lin RR, Wu ZY, et al. Genetic analysis of Chinese patients with early-onset dementia using next-generation sequencing. Clin Interv Aging. 2020;15:1831–9.
Ulugut H, Stek S, Wagemans LEE, Jutten RJ, Keulen MA, Bouwman FH, et al. The natural history of primary progressive aphasia: beyond aphasia. J Neurol. 2022;269:1375–85.
Foxe D, Irish M, Hu A, Carrick J, Hodges JR, Ahmed RM, et al. Longitudinal cognitive and functional changes in primary progressive aphasia. J Neurol. 2021;268:1951–61.
Olney NT, Ong E, Goh SM, Bajorek L, Dever R, Staffaroni AM, et al. Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimers Dement. 2020;16:49–59.
Poos JM, Russell LL, Peakman G, Bocchetta M, Greaves CV, Jiskoot LC, et al. Impairment of episodic memory in genetic frontotemporal dementia: a GENFI study. Alzheimers Dement (Amst). 2021;13:e12185.
Alberici A, Gobbo C, Panzacchi A, Nicosia F, Ghidoni R, Benussi L, et al. Frontotemporal dementia: impact of P301L tau mutation on a healthy carrier. J Neurol Neurosurg Psychiatry. 2004;75:1607–10.
Makaretz SJ, Quimby M, Collins J, Makris N, McGinnis S, Schultz A, et al. Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2018;89:1024–31.
Lu J, Huang L, Lv Y, Peng S, Xu Q, Li L, et al. A disease-specific metabolic imaging marker for diagnosis and progression evaluation of semantic variant primary progressive aphasia. Eur J Neurol. 2021;28:2927–39.
留言 (0)